Merus’s big bispecific test approaches
Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?
Black Diamond picks its lung cancer battle
The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.
A cancer pipeline cull from AbbVie
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
Like Merck, Bristol goes to China
Yet another rich ADC deal is struck as Bristol Myers Squibb ties up with China’s SystImmune.
ESMO Asia 2023 – deaths raise doubts about Merus’s Rybrevant challenger
Merus still hopes for a future for MCLA-129, but the doors are closing.
ESMO 2023 – butterflies for J&J
Rybrevant underwhelms in Mariposa, handing a possible advantage back to AstraZeneca’s Tagrisso.
Bridge mirrors Black Diamond and Blueprint’s search for something better
The companies have all switched to improved fourth-generation EGFR projects in lung cancer, a fact that likely shows how competitive this field has become.
World Lung 2023 – Flaura2 leaves a gap open for J&J
AstraZeneca’s trial lives up to its billing, though the benefit might be subgroup-driven, and comes at the cost of toxicity.
